UroGen Pharma Ltd
- Market cap
- 1.99B
- P/E (TTM)i
- -20.66
- P/Bi
- -15.02
- EPSi
- -3.19
- Div yieldi
- 0.00%
- 52W posi
- 71%
Anonymous reader poll. Unscientific, not investment advice.
UroGen Pharma Ltd shares were changing hands at 40.70, down 1.76% on the day. That leaves the company valued at approximately 1.99B, the #2773 most valuable US-listed company we track. Wall Street's 5-analyst consensus lands on Buy, with a price target averaging 60.20 (+48% from here). Against a 52-week band of 16.18-50.81, the shares are currently 71% of the way up.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 4% of the universe, above its 200-day average.
- Signal has read BUY for 6 months.
- Its last 7 Buy calls have averaged +17% over the following quarter.
- Recent price momentum is +74.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 12.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 41.43
- Open
- 40.70
- Day range
- 40.64 - 41.93
- Avg price
- 41.07
- Volume
- 486.48K
- Turnover
- 19.98M
- Turnover ratei
- 1.12%
- Volume ratioi
- 0.61
- Amplitudei
- 3.11%
- 52-week rangei
- 16.18 - 50.81
Valuation
- P/Ei
- -12.76
- P/E (TTM)i
- -20.66
- P/Bi
- -15.02
- EPSi
- -3.19
- Book value / shi
- -2.71
- Net profit
- -155.93M
- Net assets
- -132.42M
Share structure
- Market cap
- 1.99B
- Float capi
- 1.77B
- Shares out
- 48.88M
- Float sharesi
- 43.41M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2017-05-04
19.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-27.28M net over the window
Short interest
- Shares short
- 6.25M
- % of floati
- 12.78%
- Days to coveri
- 9.16
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of UroGen Pharma Ltd (URGN)?
UroGen Pharma Ltd last traded at 40.70. The quote on this page refreshes every few seconds while US markets are open.
What is UroGen Pharma Ltd's market cap?
About 1.99B.
What is the P/E ratio of UroGen Pharma Ltd?
The trailing twelve-month P/E is -20.66. The Valuation tab shows it against the stock's own five-year range.
Does UroGen Pharma Ltd pay a dividend?
UroGen Pharma Ltd does not currently pay a regular dividend.
Is UroGen Pharma Ltd a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 60.20, which implies 47.9% upside from the current price. This is not investment advice.
What is UroGen Pharma Ltd's StockVane Quant Rating?
The StockVane Momentum strategy currently rates UroGen Pharma Ltd a B (Buy). Twelve-month momentum in the top 4% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 05:49:07 · For reference only, not investment advice and not tailored to your situation.